225 related articles for article (PubMed ID: 19187276)
1. Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Haas S
Eur J Haematol; 2009 May; 82(5):339-49. PubMed ID: 19187276
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban: an oral direct inhibitor of factor Xa.
Gulseth MP; Michaud J; Nutescu EA
Am J Health Syst Pharm; 2008 Aug; 65(16):1520-9. PubMed ID: 18693206
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST; Scott LJ; Plosker GL
Drugs; 2009; 69(13):1829-51. PubMed ID: 19719335
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.
Trujillo T; Dobesh PP
Drugs; 2014 Sep; 74(14):1587-603. PubMed ID: 25178252
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
McDonald H; Diamantopoulos A; Wells P; Lees M; Folkerts K; Forster F; Ananthapavan J
J Med Econ; 2012; 15(5):817-28. PubMed ID: 22494267
[TBL] [Abstract][Full Text] [Related]
10. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
[TBL] [Abstract][Full Text] [Related]
11. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
Yong CM; Boyle AJ
Curr Vasc Pharmacol; 2010 Jan; 8(1):5-11. PubMed ID: 19485937
[TBL] [Abstract][Full Text] [Related]
12. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
13. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
15. Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Romualdi E; Ageno W
Expert Opin Investig Drugs; 2011 Apr; 20(4):495-505. PubMed ID: 21385107
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
Kwong LM
Vasc Health Risk Manag; 2011; 7():461-6. PubMed ID: 21822393
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban, the first oral, direct factor Xa inhibitor.
Fassiadis N
Expert Opin Pharmacother; 2009 Dec; 10(18):2945-6. PubMed ID: 19925048
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
19. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
